BiologicsMD is based in Fayetteville, Arkansas and was formed in 2010 to accelerate the development of academic discoveries into new medications that will enhance people's lives.  The company won over $600,000 in cash, awards, and investments at six major entrepreneurial business plan competitions.   In 2011 the firm was selected to receive a $2.3 million U.S. Department of Defense research contract to continue research on its innovative osteoporosis compound.  The award was through the U.S. Department of Defense Peer Reviewed Medical Research Program of the Office of the Congressionally Directed Medical Research Programs (CDMRP).  This program received more than 600 applications and fewer than 10 percent were recommended for funding.

The company's lead compound, PTH-CBD™, is focused on helping patients avoid the devastating effects of osteoporosis.  The next steps in the PTH-CBD development program include manufacturing process development, preclinical toxicology testing, preparation and submission of an Investigation New Drug (IND) application, and the completion of a Phase I clinical trial.   PTH-CBD™ promises five times the efficacy of available bisphosphonate treatments with fewer side effects.  According to the National Osteoporosis Foundation, one in two women and one in four men will be diagnosed with osteoporosis in their lifetime.